Novartis AG
Dosing Regimen of Siponimod

Abstract:

The present disclosure relates to a novel dosing regimen for the administration of siponimod or pharmaceutically acceptable co-crystals or salts thereof, in the treatment of stroke, in particular intracerebral hemorrhage (ICH).